+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-05-17Number of Pages: 71

Exocrine Pancreatic Insufficiency Market - (Therapeutic - Pancreatic Enzyme Replacement Therapy (Creon, Zenpep, Pancreaze, Ultresa, Viokase, Pertzye) and Phase III Drugs; Diagnostic Test - Blood Tests, Endoscopic ultra-sonography, MRI, and CT Scanning) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 - 2023

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of exocrine pancreatic enzymes, resulting in the inability to digest food properly, a condition called maldigestion. These enzymes consist of lipases for fat digestion, proteases for protein digestion, and amylases for starch digestion. EPI results from various diseases such as cystic fibrosis, chronic pancreatitis, pancreatic cancer, cytomegalovirus infection, and HIV/AIDS. The symptoms of EPI are maldigestion or malabsorption and specifically malnutrition with weight loss, steatorrhoea, vitamin deficiencies (especially of vitamins A, D, E, K), and diabetes mellitus, which in turn may also be a cause of EPI. Diagnosis of exocrine pancreatic insufficiency (EPI) is primarily clinical. It may go unobserved because the signs and symptoms are similar to those of other GI diseases or because the signs and symptoms are not always evident due to dietary restrictions.

Management of EPI is based primarily on pancreatic enzyme replacement therapy (PERT), but could also include lifestyle modifications and vitamin supplementation. Increase in prevalence of diabetes and rise in prevalence of cystic fibrosis and chronic pancreatitis drives the exocrine pancreatic insufficiency market. However, drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), have required the manufacturers to obtain regulatory approvals before marketing their products because of possible adverse effects and inadequate effectiveness. These stringent FDA regulations have made approval of pancrelipase products difficult. This is hampering market growth. The global exocrine pancreatic insufficiency market was valued at US$ 707.0 Mn in 2014 and is projected to reach US$ 1,588.8 Mn by 2023, expanding at a CAGR of 8.3% from 2015 to 2023. 

The pancreatic enzyme replacement therapy segment has been sub-segmented into Creon, Zenpep, Pancreaze, Ultresa, Viokace, and Pertzye. Creon accounted for the largest share of the EPI market in the U.S. in 2014 and is expected to lead this market in the next few years. Ultresa is expected to grow at the highest rate as it is technologically advanced compared to other products and has several advantages over them. Ultresa, formerly known as ‘Ultrase’, is an orally administered porcine pancreatic enzyme preparation (PEP) that was previously indicated for the treatment of EPI in adults and children. The market for Ultresa is likely to expand at the highest rate owing to high preference by patients and as it provides effective treatment option to the patient.

Based on diagnostic test, the exocrine pancreatic insufficiency market has been segmented into blood tests, endoscopic ultra-sonography (EUS), magnetic resonance imaging (MRI), and CT scanning. Computerized tomography (CT) scan is the traditionally used and most adopted imaging technique. The segment accounted for the majority share of the market in 2014. However, growth of the segment is expected to slow down in the near future due to introduction of advanced techniques in the market. Magnetic resonance imaging (MRI) is a more sensitive technique compared to CT and is emerging as the radiological imaging modality of choice for the assessment of chronic pancreatitis with unequivocal CT scan. Hence, the MRI segment is likely to expand at the highest CAGR during the forecast period. 

Based on geography, the exocrine pancreatic insufficiency market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the global exocrine pancreatic insufficiency (EPI) market in 2014. The region is expected to lead the market in the next few years. Increasing prevalence of exocrine pancreatic insufficiency and other causative diseases such as cystic fibrosis (CF) and chronic pancreatitis (CP) in the U.S. is a major factor contributing to the considerable market share of North America. According to recent data by Aptalis (Allergan), in the U.S., CP is estimated to occur in 28 to 42 cases per 100,000 adult population. Of these 30% to 40% will develop EPI over a ten-year period. 

The exocrine pancreatic insufficiency market in Asia Pacific is anticipated to witness the fastest growth rate during the forecast period as compared to North America and Europe. Increasing geriatric population in countries such as Japan, China, and Singapore have accelerated the demand for accurate and reliable treatment products, thereby driving the market in the region. Moreover, rising disposable income and increase in health care infrastructure in countries such as India, China, and Malaysia are likely to support market growth. The exocrine pancreatic insufficiency market in Latin America is projected to expand at a significant CAGR during the forecast period from 2015 to 2023. Improving health care scenario, rising prevalence of chronic diseases, and growing investments by market players are the major factors fueling the growth of the exocrine pancreatic insufficiency market in Latin America.

Major players operating in the global exocrine pancreatic insufficiency market include AbbVie, Inc., Nordmark Arzneimittel GmbH & Co. KG, Allergan plc, Digestive Care, Inc., and Janssen Pharmaceuticals, Inc.

exocrine-pancreatic-insufficiency

 

Table of Content

1. Preface
    1.1. Report Description
    1.2. Market Segmentation
    1.3. Research Methodology
    1.4. Assumptions

2. Executive Summary
    2.1. Market Snapshot: Exocrine Pancreatic Insufficiency, 2014 & 2023
    2.2. Comparative Analysis: Exocrine Pancreatic Insufficiency Market, by Geography (%), 2014 & 2023 
    2.3. U.S. Exocrine Pancreatic Insufficiency Market, by Type, 2014 (US$ Mn)

3. Exocrine Pancreatic Insufficiency Market – Industry Analysis
    3.1. Introduction and Market Definition
    3.2. Treatment other than Drug therapy
    3.3. Market Dynamics
    3.4. Market Attractiveness Analysis of Global Exocrine Pancreatic Insufficiency Market, by Geography
    3.5. Impact Analysis
    3.6. Pipeline Analysis (Phase II and I) Tabular Presentation
    3.7. Competitive Analysis 

4. Global Exocrine Pancreatic Insufficiency Market– By Therapeutics 2013-2023 (US$ Mn)
    4.1. Overview
    4.2. Pancreatic Enzyme Replacement Therapy (PERT) Drugs
          4.2.1. Creon
          4.2.2. Zenpep
          4.2.3. Pancreaze
          4.2.4. Ultresa
          4.2.5. Viokace
          4.2.6. Pertzye
    4.3. Exocrine Pancreatic Insufficiency Drugs, Pipeline Analysis, Post launch - 2023, Sollpura (Liprotamase)

5. Global Exocrine Pancreatic Insufficiency Market – By Diagnostic Tests
    5.1. Overview
    5.2. Blood Tests
    5.3. Endoscopic Ultra-Sonography (EUS)
    5.4. Magnetic Resonance Imaging (MRI)
    5.5. CT Scanning

6. Global Exocrine Pancreatic Insufficiency Market – By Geography
    6.1. North America
          6.1.1. U.S.
          6.1.2. Canada
          6.1.3. Rest of North America
    6.2. Europe
          6.2.1. U.K.
          6.2.2. Germany
          6.2.3. Rest of Europe
    6.3. Asia Pacific
          6.3.1. China
          6.3.2. Japan
          6.3.3. Rest of APAC
    6.4. Latin America
          6.4.1. Brazil
          6.4.2. Mexico
          6.4.3. Rest of LATAM
    6.5. Rest of the World
          6.5.1. South Africa
          6.5.2. Russia
          6.5.3. Rest of RoW

7. Company Profiles
    7.1. Abbvie Inc.
    7.2. Allergan plc.
    7.3. Nordmark Arzneimittel GmbH & Co. KG 
    7.4. Digestive Care, Inc.
    7.5. Cilian AG 
    7.6. Anthera Pharmaceuticals Inc.
    7.7. Janssen Pharmaceuticals Inc. 
    7.8. AzurRx BioPharma, Inc.

List of Figures

FIG. 1 Market Segmentation
FIG. 2 Global Exocrine Pancreatic Insufficiency (EPI) Market Share, by Geography, 2014 
FIG. 3 Global Exocrine Pancreatic Insufficiency (EPI) Market Share, by Geography, 2023
FIG. 4 Exocrine Pancreatic Insufficiency (EPI) Market, by Type, 2014 (US$ Mn)
FIG. 5 Global Exocrine Pancreatic Insufficiency Market, by Geography, Value (%), 2014
FIG. 6 U.S. Exocrine Pancreatic Insufficiency Market, by Key Players, 2014 (%)
FIG. 7 U.S. Creon Market Revenue, (US$ Mn), 2013–2023
FIG. 8 U.S. Zenpep Market Revenue, (US$ Mn), 2013–2023
FIG. 9 U.S. Pancreaze Market Revenue, (US$ Mn), 2013–2023
FIG. 10 U.S. Ultresa Market Revenue, (US$ Mn), 2013–2023
FIG. 11 U.S. Viokace Market Revenue, (US$ Mn), 2013–2023
FIG. 12 U.S Pertzye Market Revenue, (US$ Mn), 2013–2023
FIG. 13 U.S Sollpura (Liprotamase) Market Revenue, (US$ Mn), 2013–2023
FIG. 14 Global Blood Tests Market Revenue, (US$ Mn), 2013–2023
FIG. 15 Global Endoscopic ultra-sonography (EUS) Market Revenue, (US$ Mn), 2013–2023
FIG. 16 Global Magnetic resonance imaging (MRI) Market Revenue, (US$ Mn), 2013–2023
FIG. 17 Global CT scanning Market Revenue, (US$ Mn), 2013–2023
FIG. 18 AbbVie, Inc., Annual Revenue, 2013–2015 (US$ Mn)
FIG. 19 Allergan plc Annual Revenue, 2012–2014 (US$ Mn)

List of Tables

TABLE 1 Exocrine Pancreatic Insufficiency (EPI): Market Snapshot 
TABLE 2 Impact Analysis
TABLE 3 Pipeline Analysis (Phase I and II): Tabular Presentation
TABLE 4 U.S. Exocrine Pancreatic Insufficiency (EPI) Market Revenue, (US$ Mn), 2013–2023
TABLE 5 Global Exocrine Pancreatic Insufficiency Market Revenue, by Diagnostic Test, (US$ Mn), 2013–2023
TABLE 6 Global Exocrine Pancreatic Insufficiency Market Revenue, by Geography, 2013–2023
TABLE 7 North America Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 8 Europe Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 9 Asia Pacific Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 10 Latin America Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 11 Rest of the World (RoW) Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or a condition called maldigestion. These enzymes primarily consist of lipases for fat digestion, proteases for protein digestion, and amylases for starch digestion. Management of EPI is based primarily on pancreatic enzyme replacement therapy (PERT), but could also include lifestyle modifications and vitamin supplementation as appropriate. Increase in prevalence of diabetes and rise in prevalence of cystic fibrosis and chronic pancreatitis accentuates the demand for exocrine pancreatic insufficiency market worldwide. The most effective treatment for exocrine pancreatic insufficiency is to successfully treat the underlying condition causing the enzyme insufficiency. Chronic pancreatitis is a benign disease often characterized by recurrent episodes of abdominal pain supplemented by progressive pancreatic exocrine and endocrine insufficiency. Treatment with antioxidants may improve quality of life and reduce pain in patients suffering from chronic pancreatitis.

This research study analyzes the market for exocrine pancreatic insufficiency (EPI) in terms of revenue (US$ Mn). The exocrine pancreatic insufficiency (EPI) market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. The report also includes key market dynamics, such as drivers, restraints, and opportunities, affecting the demand for exocrine pancreatic insufficiency (EPI) treatment products globally. Comparative analysis has also been included in the executive summary that resembles the percentage market share of each regions in 2014 and 2023 respectively.  

This report provides in-depth analysis of the exocrine pancreatic insufficiency market. The stakeholders for this report include companies involved in the manufacturing of products used in treatment of exocrine pancreatic insufficiency. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition in different regions.

The market overview section of this report analyzes market dynamics such as drivers, restraints and opportunities that influence the exocrine pancreatic insufficiency market in the current and future scenario. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the exocrine pancreatic insufficiency market. All these factors will help the market players to decide about the business strategies and plans to be incurred in future for strengthening their position in the global market.

The exocrine pancreatic insufficiency market by therapeutic has been segmented as pancreatic enzyme replacement therapy (PERT) drugs and diagnostic tests. PERT drugs involves Creon, Zenpep, Pancreaze, Ultresa and Pertzye. The diagnostic tests involves blood tests, endoscopic ultra-sonography, magnetic resonance imaging and CT scanning.

Geography wise, the exocrine pancreatic insufficiency market has been differentiated into five major regions: North America, Asia Pacific, Europe, Latin America and Rest of the World. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., Japan China, Russia, Brazil, Mexico and South Africa have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the exocrine pancreatic insufficiency market in various regions has been provided in this section.

The report provides market estimation of exocrine pancreatic insufficiency market in terms of revenue (US$ Mn) for all the segments and sub segments with CAGR % for period 2015 to 2023, considering 2014 as the base year.  Furthermore, the report incorporates market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2014.

The report concludes with the company profile section which includes company overview, financial overview, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Abbvie, Inc., Allergan plc, Digestive Carew, Inc., Cilian AG, Anthera Pharmaceuticals, Inc. and AzuRx Biopharma, Inc. are among others.

The global exocrine pancreatic insufficiency market is segmented into the following categories:

Global Exocrine Pancreatic Insufficiency Market, by Therapeutics

  • Pancreatic Enzyme Replacement Therapy (PERT) Drugs
    • Creon
    • Zenpep
    • Pancreaze
    • Ultresa
    • Viokace
    • Pertzye
  • Exocrine Pancreatic Insufficiency Drugs, Pipeline Analysis, Sollpura (Liprotamase)

Global Exocrine Pancreatic Insufficiency Market, by Diagnostic Tests

  • Blood Tests
  • Endoscopic Ultra-Sonography (EUS)
  • Magnetic Resonance Imaging (MRI)
  • CT Scanning

Global Exocrine Pancreatic Insufficiency Market, by Geography

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Rest of the World
    • South Africa
    • Russia
    • Rest of RoW


 
 
Back To Top